Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial.
Mao YangYuhao ZhaoYongsheng LiXuya CuiFatao LiuWenguang WuXu-An WangMaolan LiYun LiuYing-Bin LiuPublished in: BMJ open (2023)
NCT04183712.
Keyphrases
- open label
- study protocol
- clinical trial
- locally advanced
- papillary thyroid
- early stage
- phase ii
- randomized controlled trial
- phase iii
- tyrosine kinase
- epidermal growth factor receptor
- advanced non small cell lung cancer
- rectal cancer
- young adults
- double blind
- placebo controlled
- childhood cancer
- cell free
- wild type
- circulating tumor cells